New gene therapy approach for Parkinson's disease
Innovative systemic gene therapy for treating Parkinson's disease
This study is testing a new way to treat Parkinson's disease by using a special gene therapy that can deliver helpful genes directly to the brain through the bloodstream, making it easier and less invasive for patients, especially those in the early stages of the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11011399 on NIH RePORTER |
What this research studies
This research focuses on developing a novel systemic gene therapy aimed at treating Parkinson's disease by overcoming barriers that have hindered previous attempts. The approach seeks to deliver therapeutic genes directly to the brain through the bloodstream, avoiding invasive procedures like direct brain injections. By improving the efficiency of gene transfer to affected brain areas, the research aims to halt disease progression or potentially cure Parkinson's disease. Patients with early-stage Parkinson's may be particularly responsive to this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage Parkinson's disease.
Not a fit: Patients with advanced Parkinson's disease or those who have significant comorbidities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that halts or reverses the progression of Parkinson's disease.
How similar studies have performed: While gene therapy for Parkinson's disease has faced challenges, this approach aims to address specific barriers that have limited previous studies, making it a novel and potentially transformative effort.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Suk, Jung Soo — University of Maryland Baltimore
- Study coordinator: Suk, Jung Soo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.